Core Viewpoint - The founder of New Oriental, Yu Minhong, announced the establishment of an e-commerce training school under Dongfang Zhenxuan, aiming to cultivate talents in e-commerce operations and live streaming [1] Group 1 - The e-commerce training school is planned to be set up in Beijing, leveraging the city's talent resources for teaching [1] - The initiative is in response to the increasing emphasis from local authorities on e-commerce, indicating a supportive regulatory environment [1] - Yu Minhong emphasized the importance of collaborative learning in the e-commerce sector, suggesting that collective exploration is more effective than solitary efforts [1]

Core Viewpoint - The founder of New Oriental and CEO of Dongfang Zhenxuan, Yu Minhong, announced plans to establish an e-commerce training school in Beijing, driven by the increasing emphasis on e-commerce by various local authorities [1]. Group 1: Company Initiatives - Dongfang Zhenxuan plans to officially launch an e-commerce training school this year [1]. - The training school aims to attract e-commerce operational talents and hosts from various regions for training in Beijing [1]. Group 2: Background Information - In June 2022, Yu Minhong indicated that New Oriental might open an e-commerce academy in the future [2].

Group 1 - The core idea of the news is that New Oriental, led by founder Yu Minhong, plans to establish an e-commerce training school this year to enhance the skills of e-commerce operators and live streamers in China [2][3] - The initiative is driven by the increasing emphasis from local authorities on e-commerce training, with a focus on collaborative learning rather than isolated efforts [2] - The training school will be located in Beijing, a hub for talent, allowing for the recruitment of experienced instructors to provide quality education [2] Group 2 - Yu Minhong had previously expressed the idea of creating an e-commerce academy during a live stream last year, highlighting the need for cultural training for e-commerce live streamers [3] - The goal of the training is not solely for profit but to elevate the overall quality of Chinese live streamers [3] - Yu Minhong intends to personally teach at the academy and will also invite renowned streamers to participate in the training [3]

Market Performance - The three major U.S. stock indices closed higher, with the Dow Jones up 0.04%, the Nasdaq up 0.9%, and the S&P 500 up 0.47% [1] - Major technology stocks saw significant gains, with Oracle rising over 9%, Microsoft and Broadcom up over 3%, and Nvidia and Meta up over 2% [1] Sector Performance - Cryptocurrency mining companies, precious metals, and non-ferrous metals led the gains, with Vista Gold up over 14%, Hut 8 up over 7%, and Pan American Silver up over 6% [1] - Other notable performers included Alcoa and Royal Gold, both rising over 5%, and Southern Copper up over 4% [1] - Retail and insurance brokerage sectors faced declines, with Macy's and Kohl's both down over 5%, and the American Reinsurance Group down over 2% [1] Chinese Stocks - The Nasdaq Golden Dragon China Index rose 0.12%, with notable gains in Chinese concept stocks such as Kingsoft Cloud, Pony.ai, and JinkoSolar, which rose up to 3.79% [1] - Other gainers included Zai Lab up 2.44%, Huazhu up 1.66%, while companies like Yum China, XPeng, Ctrip, Bilibili, NIO, Li Auto, and New Oriental experienced declines, with New Oriental down 4.24% [1]

Market Overview - On February 9, US stock indices opened lower, with the Nasdaq down 0.37%, the Dow Jones down 0.21%, and the S&P 500 down 0.26% [1] - The Nasdaq China Golden Dragon Index fell by 0.7%, with notable declines in several Chinese concept stocks, including Li Auto, Bilibili, New Oriental, and NIO, which all dropped over 3% [2] Chinese Concept Stocks - Li Auto decreased by 3.80% to $18.250 - Bilibili and New Oriental both fell by 3.30%, with prices at $30.490 and $60.650 respectively - Other significant declines included Ctrip Group down 1.95% to $58.240, Baidu down 1.64% to $143.540, and JD Group down 1.10% to $27.760 [3] Large Tech Stocks - Large technology stocks showed mixed performance, with SanDisk dropping over 4% and AMD down nearly 2%, while Oracle saw an increase of nearly 5% [4] - SanDisk fell by 4.55% to $570.725, while Oracle rose by 4.93% to $149.855 [5]

Group 1 - The core point of the article is that First Beijing Investment Co., Ltd. has reduced its stake in New Oriental Education & Technology Group Inc. (09901) by selling 1.4412 million shares at a price of HKD 49.0174 per share, totaling approximately HKD 70.6439 million [1] - After the reduction, the latest number of shares held by First Beijing is approximately 188 million, representing a holding percentage of 10.96% [1]

Group 1 - The core point of the article is that First Beijing Investment Co., Ltd. has reduced its stake in New Oriental Education & Technology Group Inc. (09901) by selling 1.4412 million shares at a price of 49.0174 HKD per share, totaling approximately 70.6439 million HKD [1] - After the reduction, First Beijing's remaining shareholding is approximately 188 million shares, representing a holding percentage of 10.96% [1]

Investment Rating - The report indicates a positive outlook for the pharmaceutical sector, particularly for innovative drugs and companies expected to reach profitability in 2025 [1][9][15]. Core Insights - The innovative drug sector is anticipated to see significant growth due to the commercialization of core products and contributions from business development (BD) revenues, with companies like BeiGene, Innovent Biologics, and others expected to achieve profitability [1][9]. - The Pharma sub-sector is projected to experience a revenue growth rate of 15-20% in 2025, with notable companies such as Hansoh Pharmaceutical and China Biologic Products leading this growth [2][10]. - The CXO sector is also expected to report strong performance, with companies like WuXi AppTec forecasting substantial revenue and profit increases [3][11]. - The medical services sector is currently valued at historical lows, with a projected revenue growth of 13% for Genscript Biotech, highlighting the importance of monitoring industry changes [4][12]. Summary by Sections Innovative Drugs - Companies expected to achieve profitability in 2025 include BeiGene, Innovent Biologics, and others, driven by increased commercialization and BD revenues [1][9]. Pharma - Revenue growth of 15-20% is expected for leading companies such as Hansoh Pharmaceutical and China Biologic Products, with a significant boost anticipated for 3SBio due to a major BD deal with Pfizer [2][10]. CXO - WuXi AppTec is projected to achieve approximately 454.56 billion RMB in revenue, reflecting a year-on-year growth of about 15.84%, with adjusted net profits expected to rise significantly [3][11]. Medical Services - Genscript Biotech is expected to see a revenue increase of 13% in 2025, emphasizing the need to focus on overseas business expansion and AI integration in traditional medicine [4][12].

Investment Rating - The report maintains a positive outlook on the pharmaceutical sector, indicating an "Overweight" rating for the industry, suggesting it will outperform the overall market [1]. Core Insights - The report highlights that the commercialization of innovative drugs, combined with licensing income, is expected to lead to profitability for several companies in 2025, including BeiGene, Innovent Biologics, and others [1][9]. - The Pharma sub-sector is projected to achieve a revenue growth rate of 15-20% in 2025 for companies like Hansoh Pharmaceutical and China Biologic Products, with a significant revenue increase expected for 3SBio due to a major business development deal with Pfizer [2][10]. - The CXO sector is also expected to show strong performance, with companies like WuXi AppTec forecasting a revenue increase of approximately 15.84% and a net profit growth of about 102.65% in 2025 [3][11]. - In the medical services sector, the report notes that valuations are at historical lows, with a projected revenue growth of 13% for GuoShengTang in 2025, emphasizing the importance of overseas business expansion and AI integration in traditional Chinese medicine [4][12]. Summary by Sections Innovative Drugs - The report anticipates that several innovative drug companies will reach profitability in 2025 due to increased commercialization and business development income [9][15]. Pharma - The Pharma sub-sector is expected to see a revenue growth of 15-20% in 2025 for key players, with 3SBio projected to achieve over 100% growth due to a significant partnership with Pfizer [2][10]. CXO - WuXi AppTec is expected to report a revenue of approximately 454.56 billion RMB in 2025, with a net profit growth of around 102.65% [3][11]. Medical Services - GuoShengTang is projected to have a revenue growth of 13% in 2025, with a focus on overseas acquisitions and AI applications in traditional medicine [4][12].

Group 1: New Oriental (EDU) - New Oriental's FY26Q2 net revenue increased by 14.7% year-on-year to $1.191 billion, slightly exceeding the previous guidance of $1.132 to $1.163 billion[9] - Operating profit reached $66.3 million, up 244.4% year-on-year, while Non-GAAP operating profit rose by 206.9% to $89.13 million[9] - The company adjusted its FY26 revenue guidance to between $5.292 billion and $5.49 billion, reflecting a year-on-year growth of 8% to 12%[12] Group 2: Financial Metrics - The target price for New Oriental is set at $78.00, representing a potential upside of 24.3% from the current price of $62.8[6] - The company's EPS for FY26 is projected to be $0.31, an increase of 3% from the previous estimate of $0.30[2] - The net profit margin improved by 0.7 percentage points to 3.8%, while Non-GAAP net profit margin increased by 1.9 percentage points to 6.1%[10] Group 3: Business Performance - New business revenue grew by 21.6% year-on-year, with non-academic tutoring registrations reaching 1.058 million, a 6.4% increase[11] - The number of active paid users for the smart learning system and devices reached 352,000, up 34.8% year-on-year[11] - The company operates 1,379 learning centers and schools, a significant increase from 1,189 in FY25Q2[11] Group 4: Market Outlook - The company expects FY26Q3 net revenue to be between $1.313 billion and $1.349 billion, indicating a year-on-year growth of 11% to 14%[12] - The overall positive performance is attributed to the recovery of new business growth and effective cost management, leading to improved profit margins[10]